Enbrel 25 mg, 50 mg Powder and solvent for solution for injection
PDF Leaflet Revision Date: 12 November 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various autoimmune conditions including rheumatoid arthritis and psoriasis.
Dosage (summary)
Adults: 25 mg twice weekly or 50 mg once weekly; adjust based on response.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use only if clearly needed; may pose infection risk to infants.
Key Drug Interactions
- Anakinra
- Abatacept
- Sulfasalazine
Contraindications
- Hypersensitivity to etanercept
- Active infections
- Sepsis
Common side effects
- Infections
- Injection site reactions
- Allergic reactions
Counselling Points
- Monitor for infections
- Avoid live vaccines
- Injection site care
Serious warnings
- Serious infections
- Tuberculosis risk
- Malignancies
Important Disclaimer
The Enbrel 25 mg, 50 mg Powder and solvent for solution for injection professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
